<DOC>
	<DOCNO>NCT00956293</DOCNO>
	<brief_summary>This study want address whether calcineurin-inhibitor ( CNI ) -free regimen six week transplantation Eurotransplant Senior Program ( ESP ) patient safe well tolerated standard treatment optimize immunosuppressive therapy benefit renal function , new-onset diabetes mellitus , cardiovascular risk , cancer allograft nephropathy .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Tolerability Everolimus de Novo Renal Transplant Recipients Participating Eurotransplant Senior Program</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criterion : Patients receive primary kidney donor age &gt; 65 year In Eurotransplant Senior Program Recipients de novo cadaveric kidney transplant Exclusion criterion : Multiorgan recipient ( e.g. , kidney pancreas ) Patients receive kidney nonheart beat donor Patients recipient ABO incompatible transplant Patients already exist antibody HLAtype receive transplant Patients receive investigational immunosuppressive drug within four week prior study entry ( Baseline visit 1 ) Patients thrombocytopenia , absolute neutrophil count &lt; 1,500/mmÂ³ leucopenia hemoglobin &lt; 6 g/dL Patients HIV , HCV RNA , Hepatitis B surface antigen positive Evidence severe liver disease Females randomization consider postmenopausal Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>